FES PET changed nodal staging, field design and boost dose in ER-positive breast cancer
In a diagnostically difficult breast cancer case, FES PET identified occult ER-positive nodal disease and materially changed radiotherapy volume and dose.
In a diagnostically difficult breast cancer case, FES PET identified occult ER-positive nodal disease and materially changed radiotherapy volume and dose.
Surgical transfer reduced contralateral submandibular mean dose by approximately 12 Gy during bilateral IMPT without compromising target coverage.
Blocking DNA double-strand-break repair enhanced proton response across seven uveal melanoma spheroid models, with DNA-PK inhibition showing the strongest effect.
Patient-specific stents improved tongue and parotid stability and were associated with substantially less hearing loss, dysphagia and dysgeusia.
Metformin plus radiotherapy prolonged survival in two syngeneic glioblastoma models while shifting macrophage and T-cell populations toward antitumor phenotypes.
Paquinimod blockade of S100A8/A9 improved survival, intestinal regeneration and barrier recovery after abdominal irradiation in preclinical models.
In the first clinical minibeam series, 86% had symptomatic improvement and one-year local control reached 92% with minibeam treatment alone.
Adding DWI/ADC produced substantially different residual GTV geometry before cervical brachytherapy, with a median Dice overlap of only 0.33.
Combined high-dose and high-LET exposure around breast implants was associated with severe capsular contracture after proton postmastectomy radiotherapy.
Multi-RBE carbon-ion optimization increased near-minimum GTV LET by 29.2% while maintaining conventional dose coverage and interfraction robustness.
A DAHANCA 35 patient decision aid was feasible and acceptable, but its value depended strongly on clinician introduction and engagement.
Twelve VMAT lattice courses produced 65% median tumor shrinkage and no local progression during short follow-up in bulky hepatocellular carcinoma.
In eight bulky tumor sites, flattening-filter VMAT lattice radiotherapy produced 75% symptom relief with no grade 3 or higher acute toxicity.
A longitudinal CT radiomics model identified post-SBRT rib fracture risk with 85% sensitivity and 71% specificity in validation.
Several cannabinoids reduced therapy-induced glioblastoma apoptosis and enhanced clonogenic survival in vitro, raising concern about concurrent use during treatment.